Transgene and NEC Start Two Clinical Trials with TG4050, an AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network
1월 8일 16:50
NEC Corporation (NEC; TOKYO: 6701), a leader in IT and network technologies, and VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the c
2019년 11월 12일 17:56
NEC Corporation (NEC; TOKYO: 6701) today announced the signing of a partnership agreement with the United Nations World Food Programme (WFP) to share expertise in biometrics technology. The knowled
2019년 8월 29일 10:09
Gavi, NEC, and Simprints to Deploy World’s First Scalable Child Fingerprint Identification Solution to Boost Immunization in Developing Countries
Gavi, the Vaccine Alliance, NEC Corporation, and Simprints Technology Ltd. have signed a memorandum of understanding on the use of biometrics to improve immunization coverage in developing countries.
2019년 6월 10일 11:59
NEC Corporation (NEC; TSE: 6701) and BostonGene Corporation (BostonGene), a Boston, Mass-based biomedical software company, today announced a US$50M series A strategic investment in BostonGene by NEC.
2019년 4월 26일 13:55
NEC and Transgene Announce a Collaboration in the Field of Individualized Cancer Immunotherapy, Leveraging NEC's AI and Transgene’s myvac™ Platform
NEC Corporation (NEC)(TOKYO:6701) and Transgene (Euronext Paris:TNG) today announced the signing of a Memorandum of Understanding (MOU) for a strategic collaboration aimed at the treatment of solid ca
2018년 10월 30일 15:40